[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 40 of about 40
1. Oki Y, Kantarjian HM, Zhou X, Cortes J, Faderl S, Verstovsek S, O'Brien S, Koller C, Beran M, Bekele BN, Pierce S, Thomas D, Ravandi F, Wierda WG, Giles F, Ferrajoli A, Jabbour E, Keating MJ, Bueso-Ramos CE, Estey E, Garcia-Manero G: Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center. Blood; 2006 Feb 1;107(3):880-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center.
  • To characterize acute megakaryocytic leukemia (FAB M7 AML), we identified 37 patients with M7 AML treated at M.D.
  • Anderson Cancer Center between 1987 and 2003 and compared them with 1800 patients with non-M7, non-M3 AML treated during the same period.
  • The median age of the M7 AML group was 56 years (range, 21-78 years); 22 patients (59%) had an antecedent hematologic disorder or myelodysplastic syndrome or both, and 7 patients (19%) had previously received chemotherapy for other malignancies.
  • Poor cytogenetic characteristics were observed in 49% of patients with M7 AML versus 33% of others (P < .001).
  • Complete remission rates were 43% with M7 AML and 57% with non-M7 AML (P = .089).
  • By multivariate analysis, M7 AML was an independent adverse prognostic factor for OS, independent of other factors including cytogenetic abnormalities (hazard ratio 1.51, P = .049).
  • These results confirm the poor prognosis of M7 AML and indicate that other biologic characteristics beyond cytogenetic abnormalities likely play a role in this disease.
  • [MeSH-major] Chromosome Aberrations. Chromosomes, Human. Leukemia, Megakaryoblastic, Acute / mortality. Leukemia, Megakaryoblastic, Acute / pathology
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Female. Humans. Male. Middle Aged. Multivariate Analysis. Myelodysplastic Syndromes / mortality. Myelodysplastic Syndromes / pathology. Myelodysplastic Syndromes / therapy. Neoplasms. Neoplasms, Second Primary / mortality. Neoplasms, Second Primary / pathology. Neoplasms, Second Primary / therapy. Primary Myelofibrosis / mortality. Primary Myelofibrosis / pathology. Primary Myelofibrosis / therapy. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16123215.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


2. Malinge S, Ragu C, Della-Valle V, Pisani D, Constantinescu SN, Perez C, Villeval JL, Reinhardt D, Landman-Parker J, Michaux L, Dastugue N, Baruchel A, Vainchenker W, Bourquin JP, Penard-Lacronique V, Bernard OA: Activating mutations in human acute megakaryoblastic leukemia. Blood; 2008 Nov 15;112(10):4220-6
Zurich Open Access Repository and Archive. Full text from .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activating mutations in human acute megakaryoblastic leukemia.
  • Oncogenic activation of tyrosine kinase signaling pathway is recurrent in human leukemia.
  • To gain insight into the oncogenic process leading to acute megakaryoblastic leukemia (AMKL), we performed sequence analyses of a subset of oncogenes known to be activated in human myeloid and myeloproliferative disorders.
  • [MeSH-major] Down Syndrome / genetics. Leukemia, Megakaryoblastic, Acute / genetics. Mutation. Neoplasm Proteins / genetics
  • [MeSH-minor] Adult. Aged. Animals. Cell Line, Tumor. Child. Child, Preschool. Female. Humans. Infant. Infant, Newborn. Male. Mice. Mice, Inbred BALB C. Middle Aged. Neoplasm Transplantation


3. Orazi A, O'Malley DP, Jiang J, Vance GH, Thomas J, Czader M, Fang W, An C, Banks PM: Acute panmyelosis with myelofibrosis: an entity distinct from acute megakaryoblastic leukemia. Mod Pathol; 2005 May;18(5):603-14
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute panmyelosis with myelofibrosis: an entity distinct from acute megakaryoblastic leukemia.
  • The WHO criteria for diagnosing acute panmyelosis with myelofibrosis are somewhat distinct from those for acute megakaryoblastic leukemia.
  • To determine the potential importance of bone marrow biopsy supplemented by immunohistochemistry in distinguishing between these two conditions, we studied 17 bone marrow biopsies of well-characterized cases of acute panmyelosis with myelofibrosis (six cases) and acute megakaryoblastic leukemia (11 cases).
  • We compared blast frequency, reticulin content, CD34 expression, and the degree of megakaryocytic differentiation of the blast cells in these two conditions.
  • Acute panmyelosis with myelofibrosis is characterized by a multilineage myeloid proliferation with a less numerous population of blasts than acute megakaryoblastic leukemia (P<0.01).
  • In the former condition, blasts are always positive with CD34, while in acute megakaryoblastic leukemia they express CD34 in 60% of the cases.
  • The blasts in acute panmyelosis with myelofibrosis only rarely express megakaryocytic antigens.
  • By contrast, acute megakaryoblastic leukemia has a significantly higher proportion of blasts expressing megakaryocytic antigens (P<0.01 with CD42b).
  • [MeSH-major] Bone Marrow Cells / pathology. Leukemia, Megakaryoblastic, Acute / pathology. Primary Myelofibrosis / pathology
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Aged, 80 and over. Antigens, CD / analysis. Child. Child, Preschool. Chromosome Aberrations. Diagnosis, Differential. Female. Flow Cytometry. Humans. Karyotyping. Male. Middle Aged

  • Genetic Alliance. consumer health - Acute Megakaryoblastic Leukemia.
  • Genetic Alliance. consumer health - Myelofibrosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15578075.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD
  •  go-up   go-down


Advertisement
4. Hussein K, Bock O, Theophile K, Schulz-Bischof K, Porwit A, Schlue J, Jonigk D, Kreipe H: MPLW515L mutation in acute megakaryoblastic leukaemia. Leukemia; 2009 May;23(5):852-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MPLW515L mutation in acute megakaryoblastic leukaemia.
  • A series of primary and secondary acute myeloid leukaemias (AML) with megakaryoblastic phenotype and myelofibrosis unrelated to PMF (n=12) was analysed for the MPL(W515K/L) mutation by pyrosequencing.
  • We conclude that MPL(W515L) occurs in a considerable proportion of acute megakaryoblastic leukaemias with myelofibrosis unrelated to PMF.
  • [MeSH-major] Leukemia, Megakaryoblastic, Acute / genetics. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics. Mutation / genetics. Primary Myelofibrosis / genetics. Receptors, Thrombopoietin / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Blast Crisis. Bone Marrow Cells. Child. Child, Preschool. Female. Humans. Janus Kinase 2 / genetics. Lasers. Male. Microdissection. Middle Aged

  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leukemia. 2009 Nov;23(11):2159-60 [19657363.001]
  • (PMID = 19194467.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Receptors, Thrombopoietin; 143641-95-6 / MPL protein, human; EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2
  •  go-up   go-down


5. Berger R, Busson M, Dastugue N, Radford-Weiss I, Michaux L, Hagemeijer A, Quilichini B, Benattar L, Bernard O, Romana SP: Acute megakaryoblastic leukemia and loss of the RUNX1 gene. Cancer Genet Cytogenet; 2006 Jan 1;164(1):71-3
Genetic Alliance. consumer health - Acute Megakaryoblastic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute megakaryoblastic leukemia and loss of the RUNX1 gene.
  • Since the RUNX1 gene contributes to megakaryopoiesis and acquired trisomy 21 is the most frequent numerical chromosome anomaly in acute megakaryoblastic leukemia (AMLK), a systematic study of RUNX1 abnormalities was performed by fluorescence in situ hybridization in AMLK patients.
  • [MeSH-major] Core Binding Factor Alpha 2 Subunit / genetics. Gene Deletion. Leukemia, Megakaryoblastic, Acute / genetics
  • [MeSH-minor] Adult. Aged. Child, Preschool. Female. Humans. Infant. Infant, Newborn. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16364766.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / RUNX1 protein, human
  •  go-up   go-down


6. Kalita K, Kharebava G, Zheng JJ, Hetman M: Role of megakaryoblastic acute leukemia-1 in ERK1/2-dependent stimulation of serum response factor-driven transcription by BDNF or increased synaptic activity. J Neurosci; 2006 Sep 27;26(39):10020-32
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of megakaryoblastic acute leukemia-1 in ERK1/2-dependent stimulation of serum response factor-driven transcription by BDNF or increased synaptic activity.
  • Serum response factor (SRF)-mediated transcription contributes to developmental and adult brain plasticity.
  • MKL1 expression was found in newborn rat cortical or hippocampal neurons in culture as well as in adult rat forebrain.

  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • Hazardous Substances Data Bank. 4-AMINOPYRIDINE .
  • Hazardous Substances Data Bank. POTASSIUM CHLORIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17005865.001).
  • [ISSN] 1529-2401
  • [Journal-full-title] The Journal of neuroscience : the official journal of the Society for Neuroscience
  • [ISO-abbreviation] J. Neurosci.
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / NS047341-01; United States / NCRR NIH HHS / RR / RR015576-06
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Amides; 0 / Brain-Derived Neurotrophic Factor; 0 / Butadienes; 0 / Chromones; 0 / Cyr61 protein, rat; 0 / Cysteine-Rich Protein 61; 0 / Immediate-Early Proteins; 0 / Intercellular Signaling Peptides and Proteins; 0 / Morpholines; 0 / Nitriles; 0 / Proto-Oncogene Proteins c-fos; 0 / Proto-Oncogene Proteins c-jun; 0 / Pyridines; 0 / Serum Response Factor; 0 / Transcription Factors; 0 / U 0126; 138381-45-0 / Y 27632; 154447-36-6 / 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one; 6384-92-5 / N-Methylaspartate; 660YQ98I10 / Potassium Chloride; BH3B64OKL9 / 4-Aminopyridine; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 1; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3; Y37615DVKC / Bicuculline
  •  go-up   go-down


7. Srinivas U, Saxena R, Bakhshi S: Acute T lymphoid and megakaryoblastic bi-lineal leukemia in a child. Indian Pediatr; 2007 Jul;44(7):541-3
Genetic Alliance. consumer health - Acute Megakaryoblastic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute T lymphoid and megakaryoblastic bi-lineal leukemia in a child.
  • Bone marrow examination showed two morphologically distinct blasts (small and large) which were confirmed on immunophenotyping to be of T-lymphoid and megakaryocytic lineages respectively.
  • This is a rare combination of bi-lineal leukemia in a child.
  • [MeSH-major] Leukemia, Megakaryoblastic, Acute / pathology. Leukemia-Lymphoma, Adult T-Cell / pathology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17684307.001).
  • [ISSN] 0019-6061
  • [Journal-full-title] Indian pediatrics
  • [ISO-abbreviation] Indian Pediatr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


8. Hsiao HH, Yang MY, Liu YC, Hsiao HP, Tseng SB, Chao MC, Liu TC, Lin SF: RBM15-MKL1 (OTT-MAL) fusion transcript in an adult acute myeloid leukemia patient. Am J Hematol; 2005 May;79(1):43-5
Genetic Alliance. consumer health - Leukemia, Myeloid.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] RBM15-MKL1 (OTT-MAL) fusion transcript in an adult acute myeloid leukemia patient.
  • The t(1;22)(p13;q13) is a nonrandom chromosomal abnormality in acute leukemia with the fusion oncogene, RBM15-MKL1 (OTT-MAL), identified recently.
  • However, this abnormality has been described only in infants and young children with acute megakaryoblastic leukemia (AMKL).
  • We report a 59-year-old male patient with the diagnosis of acute myeloid leukemia, subtype M1, who harbors an abnormal chromosome +der(1)t(1;22)(p13;q13).
  • This unusual abnormality is rare in adult cases of leukemia, and in children it is restricted to AMKL.
  • [MeSH-major] Chromosomes, Human, Pair 1. Chromosomes, Human, Pair 5. DNA-Binding Proteins / genetics. Leukemia, Myeloid / genetics. Oncogene Proteins, Fusion / genetics. RNA-Binding Proteins / genetics. Translocation, Genetic
  • [MeSH-minor] Acute Disease. Adult. Base Sequence. DNA Primers. Humans. Male. Reverse Transcriptase Polymerase Chain Reaction. Trans-Activators

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2005 Wiley-Liss, Inc.
  • (PMID = 15849773.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / DNA-Binding Proteins; 0 / MKL1 protein, human; 0 / Oncogene Proteins, Fusion; 0 / RBM15 protein, human; 0 / RNA-Binding Proteins; 0 / Trans-Activators
  •  go-up   go-down


9. Delgado-Lamas JL, Garcés-Ruiz OM, Aguilar-López LB, Borjas-Gutiérrez C, Flores-Márquez MR, Luna-Zaizar H, Delgado-Chávez R: [A clinical and therapeutic analysis in acute megakaryoblastic leukemia]. Rev Med Inst Mex Seguro Soc; 2009 Mar-Apr;47(2):193-8
Genetic Alliance. consumer health - Acute Megakaryoblastic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A clinical and therapeutic analysis in acute megakaryoblastic leukemia].
  • OBJECTIVE: to show clinical and therapeutic findings in patients with diagnosis of acute megakaryoblastic leukemia (AML).
  • [MeSH-major] Leukemia, Megakaryoblastic, Acute / diagnosis. Leukemia, Megakaryoblastic, Acute / therapy
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Male. Middle Aged. Retrospective Studies. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19744390.001).
  • [ISSN] 0443-5117
  • [Journal-full-title] Revista médica del Instituto Mexicano del Seguro Social
  • [ISO-abbreviation] Rev Med Inst Mex Seguro Soc
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


10. Takita J, Motomura A, Koh K, Ida K, Taki T, Hayashi Y, Igarashi T: Acute megakaryoblastic leukemia in a child with the MLL-AF4 fusion gene. Eur J Haematol; 2009 Aug;83(2):149-53
Genetic Alliance. consumer health - Acute Megakaryoblastic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute megakaryoblastic leukemia in a child with the MLL-AF4 fusion gene.
  • Mixed-lineage leukemia (MLL) rearrangements are commonly observed in childhood acute lymphoblastic and myeloid leukemia, as well as therapy-related leukemia.
  • However, the occurrence of MLL rearrangements in acute megakaryoblastic leukemia (AMKL) is very rare.
  • MLL-AF4 is derived from t(4;11)(q21:q23) and occurs exclusively in B-cell lineage leukemia.
  • To our knowledge, MLL-AF4 as well as t(4;11)(q21:q23) has not been reported in adult and childhood AMKL.
  • Thus, our case provides new insight into the molecular mechanisms of MLL-AF4-associated leukemia.
  • [MeSH-major] Leukemia, Megakaryoblastic, Acute / genetics. Myeloid-Lymphoid Leukemia Protein / genetics. Oncogene Proteins, Fusion / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19459927.001).
  • [ISSN] 1600-0609
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / MLL-AF4 fusion protein, human; 0 / Oncogene Proteins, Fusion; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein
  •  go-up   go-down


11. Savaşan S, Buck S, Raimondi SC, Becton DL, Weinstein H, Chang M, Ravindranath Y: CD36 (thrombospondin receptor) expression in childhood acute megakaryoblastic leukemia: in vitro drug sensitivity and outcome. Leuk Lymphoma; 2006 Oct;47(10):2076-83
Hazardous Substances Data Bank. DAUNORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD36 (thrombospondin receptor) expression in childhood acute megakaryoblastic leukemia: in vitro drug sensitivity and outcome.
  • The outcome for children with acute megakaryoblastic leukemia (AMKL) remains poor, except for cases associated with Down syndrome (DS).
  • CD36 expression in acute myeloid leukemia cases other than AMKL was not associated with increased in vitro drug sensitivity.
  • [MeSH-major] Antigens, CD36 / biosynthesis. Gene Expression Regulation, Neoplastic. Leukemia, Megakaryoblastic, Acute / complications. Leukemia, Megakaryoblastic, Acute / metabolism
  • [MeSH-minor] Adolescent. Adult. Biomarkers, Tumor. Cell Membrane / metabolism. Child. Child, Preschool. Cytarabine / pharmacology. Daunorubicin / pharmacology. Down Syndrome / complications. Humans. Immunophenotyping. Infant. Infant, Newborn. Sensitivity and Specificity. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Megakaryoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2006 Oct;47(10):2004-5 [17071466.001]
  • (PMID = 17071479.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-21765; United States / NCI NIH HHS / CA / U10 CA 30969
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD36; 0 / Biomarkers, Tumor; 04079A1RDZ / Cytarabine; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


12. Taketani T, Taki T, Sako M, Ishii T, Yamaguchi S, Hayashi Y: MNX1-ETV6 fusion gene in an acute megakaryoblastic leukemia and expression of the MNX1 gene in leukemia and normal B cell lines. Cancer Genet Cytogenet; 2008 Oct 15;186(2):115-9
MedlinePlus Health Information. consumer health - Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MNX1-ETV6 fusion gene in an acute megakaryoblastic leukemia and expression of the MNX1 gene in leukemia and normal B cell lines.
  • Patients with infant acute myeloid leukemia (AML) who carry a t(7;12)(q36;p13) translocation have been reported to have a poor clinical outcome.
  • A 23-month-old girl with acute megakaryoblastic leukemia (AMKL) exhibited chromosome abnormalities, including add(7)(q22), and del(12)(p12p13).
  • The MNX1 expression by RT-PCR was significantly more frequent in Epstein-Barr virus-transformed B-cell lines derived from normal adult lymphocytes than in leukemic cell lines.
  • [MeSH-major] B-Lymphocytes / metabolism. Gene Fusion. Homeodomain Proteins / genetics. Leukemia / genetics. Leukemia, Megakaryoblastic, Acute / genetics. Proto-Oncogene Proteins c-ets / genetics. Repressor Proteins / genetics. Transcription Factors / genetics

  • Genetic Alliance. consumer health - Acute Megakaryoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18940475.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ETS translocation variant 6 protein; 0 / Homeodomain Proteins; 0 / MNX1 protein, human; 0 / Proto-Oncogene Proteins c-ets; 0 / Repressor Proteins; 0 / Transcription Factors
  •  go-up   go-down


13. Lo KC, Chalker J, Strehl S, Neat M, Smith O, Dastugue N, Kearney L, Izraeli S, Kempski H, Cowell JK: Array comparative genome hybridization analysis of acute lymphoblastic leukaemia and acute megakaryoblastic leukaemia in patients with Down syndrome. Br J Haematol; 2008 Sep;142(6):934-45
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Array comparative genome hybridization analysis of acute lymphoblastic leukaemia and acute megakaryoblastic leukaemia in patients with Down syndrome.
  • Twenty-five cases of B-cell precursor acute lymphoblastic leukaemia (ALL) from Down syndrome (DS) patients were analyzed using array comparative genomic hybridization (aCGH) and compared with two other subgroups of non-DS patients with ALL; five cases with high-hyperdiploidy (HH) and nine cases with ETV6-RUNX1 positive clones.
  • Seven cases of DS-acute megakaryoblastic leukaemia (AMKL) were also included, DS-ALL cases showed relatively stable karyotypes with cryptic losses and gains that most frequently involved chromosomes X, 1, 2, 9, 11, 16, and 17.
  • [MeSH-major] Chromosome Aberrations. Down Syndrome / genetics. Leukemia, Megakaryoblastic, Acute / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Cohort Studies. Comparative Genomic Hybridization. Core Binding Factor Alpha 2 Subunit / genetics. Female. Humans. Karyotyping. Male. Oncogene Proteins, Fusion / genetics. Ploidies. Young Adult

  • Genetic Alliance. consumer health - Down Syndrome.
  • MedlinePlus Health Information. consumer health - Down Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Br J Haematol. 2009 Jun;146(1):113-5 [19344409.001]
  • (PMID = 18557744.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / Oncogene Proteins, Fusion; 0 / TEL-AML1 fusion protein
  •  go-up   go-down


14. Ahmad F, Dalvi R, Das BR, Mandava S: Novel t(8;17)(q23;q24.2) and t(9;22)(p24.1;q12.2) in acute megakaryoblastic leukemia AML-M7 subtype in an adult patient. Cancer Genet Cytogenet; 2009 Sep;193(2):112-5
Genetic Alliance. consumer health - Acute Megakaryoblastic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel t(8;17)(q23;q24.2) and t(9;22)(p24.1;q12.2) in acute megakaryoblastic leukemia AML-M7 subtype in an adult patient.
  • The strong association of diagnostic karyotype with clinical outcome has made cytogenetics one of the most valuable diagnostic and prognostic tools for acute myeloid leukemia (AML).
  • The subtype M7 is a rare disease of the megakaryoblastic lineage and is mostly associated with complex abnormal karyotype.
  • We describe the clinical, morphologic, immunophenotypic, and cytogenetic findings in the case of a 39-year-old man with acute megakaryoblastic leukemia (AML-M7).
  • Cytogenetic analysis revealed two translocations, t(8;17)(q23;q24.2) and t(9;22)(p24.1;q12.2), at presentation; to our knowledge, this combination is a novel finding for acute megakaryoblastic leukemia.
  • [MeSH-major] Chromosomes, Human. Leukemia, Megakaryoblastic, Acute / genetics. Translocation, Genetic
  • [MeSH-minor] Adult. Humans. In Situ Hybridization, Fluorescence. Karyotyping. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19665073.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Scharenberg MA, Chiquet-Ehrismann R, Asparuhova MB: Megakaryoblastic leukemia protein-1 (MKL1): Increasing evidence for an involvement in cancer progression and metastasis. Int J Biochem Cell Biol; 2010 Dec;42(12):1911-4
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Megakaryoblastic leukemia protein-1 (MKL1): Increasing evidence for an involvement in cancer progression and metastasis.
  • Megakaryoblastic leukemia protein-1 (MKL1), also termed MAL, MRTF-A, and BSAC, belongs to the MRTF family of transcription factors that share evolutionary conserved domains required for actin-binding, homo- and heterodimerization, high-order chromatin organization and transcriptional activation.
  • MKL1 regulates many processes, including muscle cell differentiation, cardiovascular development, remodeling of neuronal networks in the developing and adult brain, megakaryocytic differentiation and migration, modulation of cellular motile functions and epithelial-mesenchymal transition.
  • Moreover, deregulation by genetic alterations and/or altered expression of MKL1 can contribute to a number of pathological processes such as coronary artery disease, sarcopenia, acute megakaryoblastic leukemia, and cancer.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20816842.001).
  • [ISSN] 1878-5875
  • [Journal-full-title] The international journal of biochemistry & cell biology
  • [ISO-abbreviation] Int. J. Biochem. Cell Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / MKL1 protein, human; 0 / MKL1 protein, mouse; 0 / Oncogene Proteins, Fusion; 0 / Trans-Activators
  •  go-up   go-down


16. Dopico Vázquez D, Gallegos Sancho MI, Alonso Curbera G, Carral Maseda A, Quindós Varela M, Antón Aparicio LM: Non-seminomatous germ-cell tumour associated with acute megakaryoblastic leukaemia. Clin Transl Oncol; 2007 May;9(5):329-31

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-seminomatous germ-cell tumour associated with acute megakaryoblastic leukaemia.
  • [MeSH-major] Leukemia, Megakaryoblastic, Acute. Mediastinal Neoplasms. Neoplasms, Germ Cell and Embryonal. Neoplasms, Multiple Primary
  • [MeSH-minor] Adult. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Intern Med. 1985 May;102(5):603-9 [2984971.001]
  • [Cites] N Engl J Med. 1990 May 17;322(20):1425-9 [2158625.001]
  • [Cites] Tumori. 1995 Jul-Aug;81(4):299-301 [8540131.001]
  • [Cites] J Clin Oncol. 2004 Jan 1;22(1):108-14 [14701772.001]
  • [Cites] J Natl Cancer Inst. 2000 Jan 5;92(1):54-61 [10620634.001]
  • [Cites] Ann Oncol. 2004 Sep;15(9):1377-99 [15319245.001]
  • [Cites] Hum Pathol. 1988 May;19(5):586-90 [2453444.001]
  • (PMID = 17525044.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


17. Kurkjian C, Patel S, Kamble R, Dunn ST, Kern W, Kharfan-Dabaja MA: Acute promyelocytic leukemia and constitutional trisomy 21. Cancer Genet Cytogenet; 2006 Mar;165(2):176-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute promyelocytic leukemia and constitutional trisomy 21.
  • The incidence of acute myelogenous leukemia (AML) in patients with constitutional trisomy 21 is estimated to be 1 in 300; it is usually seen before age four.
  • Clinical and epidemiological data confirm the improved life expectancy of patients with Down syndrome and their increased susceptibility to the development of leukemia, among other cancers.
  • The most frequent subtype of AML associated with Down syndrome is acute megakaryoblastic leukemia (FAB: M7).
  • The description of acute promyelocytic leukemia (APL) in adult patients with Down syndrome is exceedingly rare.
  • Herein, we describe the unusual presentation, treatment, results, and clinical course of an adult patient with APL and constitutional trisomy 21 and provide a brief review of the literature.
  • [MeSH-major] Down Syndrome. Leukemia, Promyelocytic, Acute / genetics
  • [MeSH-minor] Adult. Humans. In Situ Hybridization, Fluorescence. Karyotyping. Male. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Down Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16527614.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Wang D, Ke XY, Wang J, Xu F, Hu YF: [Correlation between MDR1 genetic polymorphism and prognosis in acute myeloid leukemia]. Zhonghua Yi Xue Za Zhi; 2007 May 29;87(20):1384-8
Genetic Alliance. consumer health - Leukemia, Myeloid.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Correlation between MDR1 genetic polymorphism and prognosis in acute myeloid leukemia].
  • OBJECTIVE: To assess the correlation of the multidrug resistance-1 (MDR1) gene single nucleotide polymorphisms (SNP) C1236T, G2677T/A and C3435T with the outcome of induction chemotherapy in patients with de novo acute myeloid leukemia (AML).
  • [MeSH-major] Leukemia, Myeloid / genetics. P-Glycoprotein / genetics. Polymorphism, Single Nucleotide
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Aged, 80 and over. Base Sequence. DNA Mutational Analysis. Female. Gene Frequency. Genotype. Humans. Leukemia, Erythroblastic, Acute / drug therapy. Leukemia, Erythroblastic, Acute / genetics. Leukemia, Erythroblastic, Acute / pathology. Leukemia, Megakaryoblastic, Acute / drug therapy. Leukemia, Megakaryoblastic, Acute / genetics. Leukemia, Megakaryoblastic, Acute / pathology. Leukemia, Monocytic, Acute / drug therapy. Leukemia, Monocytic, Acute / genetics. Leukemia, Monocytic, Acute / pathology. Leukemia, Myeloid, Acute / drug therapy. Leukemia, Myeloid, Acute / genetics. Leukemia, Myeloid, Acute / pathology. Leukemia, Myelomonocytic, Acute / drug therapy. Leukemia, Myelomonocytic, Acute / genetics. Leukemia, Myelomonocytic, Acute / pathology. Leukemia, Promyelocytic, Acute / drug therapy. Leukemia, Promyelocytic, Acute / genetics. Leukemia, Promyelocytic, Acute / pathology. Male. Middle Aged. P-Glycoproteins. Prognosis. Remission Induction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17785057.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / ABCB1 protein, human; 0 / P-Glycoprotein; 0 / P-Glycoproteins
  •  go-up   go-down


19. Ru YX, Zhao SY, Liu JH, Mi YC, Zhu XF, Wang HJ, Wang JX: [Ultrastructural characteristics of megakaryocytes in 11 patients with acute megakaryocytic leukemia]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Aug;15(4):720-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ultrastructural characteristics of megakaryocytes in 11 patients with acute megakaryocytic leukemia].
  • The purpose of study was to investigate the ultrastructural features of leukemic megakarocyte (LMK) in patients with acute megakaryocytic leukemia (M(7)).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17708790.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] EC 1.11.1.7 / Peroxidase
  •  go-up   go-down


20. Garderet L, Labopin M, Gorin NC, Polge E, Baruchel A, Meloni G, Ortega J, Vossen J, Bunjes D, Leverger G, Blaise D, Ferrant A, Brune M, Dore E, Gadner H, Zintl F, Yaniv I, Dini G, Frassoni F, Acute Leukemia Working Party and Pediatric Working Party of the European Group for Blood and Marrow Transplantation: Hematopoietic stem cell transplantation for de novo acute megakaryocytic leukemia in first complete remission: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT). Blood; 2005 Jan 1;105(1):405-9
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hematopoietic stem cell transplantation for de novo acute megakaryocytic leukemia in first complete remission: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT).
  • Acute megakaryoblastic leukemia (M7 AML) is a highly aggressive disease.
  • We evaluated outcomes in 57 children (11 with Down syndrome) and 69 adults with M7 AML after first complete remission (CR1) following autologous or HLA-identical allogeneic transplantation.
  • Results for autologous transplantation were (children and adults, respectively): engraftment, 90% and 100%; 3-year treatment-related mortality (TRM) rate, 3% and 8%; relapse rate, 45% and 64%; leukemia-free survival (LFS) rate, 52% and 27%; overall survival (OS) rate, 61% and 30%.
  • We conclude that M7 AML patients in CR1 (except children with Down syndrome, who already have better outcomes) can benefit from transplantation.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Leukemia, Megakaryoblastic, Acute / pathology. Leukemia, Megakaryoblastic, Acute / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Disease-Free Survival. Down Syndrome / complications. Europe. Female. Graft vs Host Disease / immunology. Humans. Infant. Male. Middle Aged. Prognosis. Recurrence. Retrospective Studies. Survival Rate. Transplantation, Autologous / adverse effects. Transplantation, Homologous / adverse effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15191953.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Fadilah SA, Raja-Zahratul-Azma RS, Leong CF: Extensive myelofibrosis responsive to treatment for acute erythroblastic leukaemia. Malays J Pathol; 2006 Jun;28(1):55-8
Hazardous Substances Data Bank. DAUNORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extensive myelofibrosis responsive to treatment for acute erythroblastic leukaemia.
  • Intense myelofibrosis is rarely associated with de novo acute myeloid leukaemia (AML) except in acute megakaryoblastic leukaemia (AML-M7) where there is diffuse marrow fibrosis as a consequence of proliferation of neoplastic myeloid cells.
  • We describe a case of extensive myelofibrosis associated with acute erythroblastic leukaemia (AML-M6) that responded to induction therapy of the leukaemia.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Erythroblastic, Acute / complications. Leukemia, Erythroblastic, Acute / drug therapy. Primary Myelofibrosis / complications. Primary Myelofibrosis / drug therapy
  • [MeSH-minor] Adult. Cytarabine / therapeutic use. Daunorubicin / therapeutic use. Female. Humans. Leukemia, Promyelocytic, Acute / complications. Leukemia, Promyelocytic, Acute / drug therapy. Leukemia, Promyelocytic, Acute / pathology

  • Genetic Alliance. consumer health - Myelofibrosis.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17694960.001).
  • [ISSN] 0126-8635
  • [Journal-full-title] The Malaysian journal of pathology
  • [ISO-abbreviation] Malays J Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Malaysia
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


22. Niu C, Zhang J, Breslin P, Onciu M, Ma Z, Morris SW: c-Myc is a target of RNA-binding motif protein 15 in the regulation of adult hematopoietic stem cell and megakaryocyte development. Blood; 2009 Sep 3;114(10):2087-96
SciCrunch. Marmoset Gene list: Data: Gene Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] c-Myc is a target of RNA-binding motif protein 15 in the regulation of adult hematopoietic stem cell and megakaryocyte development.
  • RNA-binding motif protein 15 (RBM15) is involved in the RBM15-megakaryoblastic leukemia 1 fusion in acute megakaryoblastic leukemia.
  • Although Rbm15 has been reported to be required for B-cell differentiation and to inhibit myeloid and megakaryocytic expansion, it is not clear what the normal functions of Rbm15 are in the regulation of hematopoietic stem cell (HSC) and megakaryocyte development.
  • Thus, Rbm15 appears to be required for normal HSC-niche interactions, for the ability of HSCs to contribute normally to adult hematopoiesis, and for normal megakaryocyte development; these effects of Rbm15 on hematopoiesis may be mediated at least in part by c-Myc.

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Development. 1999 Dec;126(23):5373-85 [10556062.001]
  • [Cites] Dev Biol. 2008 Feb 1;314(1):100-11 [18174108.001]
  • [Cites] Genetics. 2000 Feb;154(2):695-712 [10655223.001]
  • [Cites] Development. 2000 Apr;127(7):1517-29 [10704397.001]
  • [Cites] Science. 2000 Mar 10;287(5459):1804-8 [10710306.001]
  • [Cites] Nature. 2000 Mar 9;404(6774):193-7 [10724173.001]
  • [Cites] Genetics. 2000 May;155(1):233-44 [10790398.001]
  • [Cites] Blood. 2009 Sep 3;114(10):2097-106 [19372257.001]
  • [Cites] Immunity. 2000 Jun;12(6):653-63 [10894165.001]
  • [Cites] Curr Biol. 2000 Jul 27-Aug 10;10(15):943-6 [10959845.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 May 8;98(10):5776-9 [11344311.001]
  • [Cites] Nat Genet. 2001 Jul;28(3):220-1 [11431691.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 4;98(25):14541-6 [11724967.001]
  • [Cites] Immunity. 2003 Feb;18(2):301-12 [12594956.001]
  • [Cites] Immunity. 2003 Oct;19(4):525-33 [14563317.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):836-41 [14574412.001]
  • [Cites] Nature. 2004 Oct 21;431(7011):1002-7 [15457180.001]
  • [Cites] J Clin Invest. 1992 Aug;90(2):358-67 [1379610.001]
  • [Cites] Genes Dev. 2004 Nov 15;18(22):2747-63 [15545632.001]
  • [Cites] Trends Cell Biol. 2005 Mar;15(3):128-37 [15752976.001]
  • [Cites] Cell. 2005 Jul 1;121(7):1109-21 [15989959.001]
  • [Cites] Blood. 2005 Aug 15;106(4):1223-31 [15860665.001]
  • [Cites] Blood. 2006 Feb 1;107(3):924-30 [16219798.001]
  • [Cites] Cancer Res. 2007 Jan 15;67(2):482-91 [17234755.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Apr 3;104(14):6001-6 [17376872.001]
  • [Cites] Leukemia. 2000 Jan;14(1):216-8 [10637500.001]
  • (PMID = 19542301.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA21675
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Myc protein, mouse; 0 / Proto-Oncogene Proteins c-myc; 0 / RNA-Binding Proteins; 0 / Rbm15 protein, mouse
  • [Other-IDs] NLM/ PMC2744570
  •  go-up   go-down


23. Pine SR, Guo Q, Yin C, Jayabose S, Druschel CM, Sandoval C: Incidence and clinical implications of GATA1 mutations in newborns with Down syndrome. Blood; 2007 Sep 15;110(6):2128-31
MedlinePlus Health Information. consumer health - Down Syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Somatic mutations in the GATA1 gene are present in almost all cases of Down syndrome (DS)-associated acute megakaryoblastic leukemia (AMKL) and transient leukemia (TL).
  • Two newborns with a GATA1 mutation subsequently developed AMKL, and none of the infants without a functional GATA1 mutation were reported to have developed leukemia.
  • [MeSH-major] Down Syndrome / genetics. GATA1 Transcription Factor / genetics. Leukemia, Megakaryoblastic, Acute / genetics. Mutation / genetics
  • [MeSH-minor] Adult. Female. Humans. Infant. Infant, Newborn. Male. Polymerase Chain Reaction. Polymorphism, Single-Stranded Conformational

  • Genetic Alliance. consumer health - Down Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17576817.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / GATA1 Transcription Factor; 0 / GATA1 protein, human
  •  go-up   go-down


24. Heald B, Hilden JM, Zbuk K, Norton A, Vyas P, Theil KS, Eng C: Severe TMD/AMKL with GATA1 mutation in a stillborn fetus with Down syndrome. Nat Clin Pract Oncol; 2007 Jul;4(7):433-8
MedlinePlus Health Information. consumer health - Stillbirth.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: A 34-year-old woman was referred for evaluation of a recent stillborn male fetus, gestational age 27 6/7 weeks, found to have congenital myeloid leukemia at autopsy.
  • DIAGNOSIS: Down syndrome with in utero onset of GATA1 mutation-positive severe transient myeloproliferative disorder/acute megakaryoblastic leukemia.
  • [MeSH-major] Down Syndrome / genetics. GATA1 Transcription Factor / genetics. Leukemia, Megakaryoblastic, Acute / genetics. Myeloproliferative Disorders / genetics. Stillbirth
  • [MeSH-minor] Adult. Autopsy. Female. Humans. Infant, Newborn. Mutation / genetics. Pregnancy

  • Genetic Alliance. consumer health - Down Syndrome.
  • Genetic Alliance. consumer health - Stillborn.
  • MedlinePlus Health Information. consumer health - Down Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17597708.001).
  • [ISSN] 1743-4262
  • [Journal-full-title] Nature clinical practice. Oncology
  • [ISO-abbreviation] Nat Clin Pract Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / GATA1 Transcription Factor; 0 / GATA1 protein, human
  •  go-up   go-down


25. Li Z, Godinho FJ, Klusmann JH, Garriga-Canut M, Yu C, Orkin SH: Developmental stage-selective effect of somatically mutated leukemogenic transcription factor GATA1. Nat Genet; 2005 Jun;37(6):613-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Acquired mutations in the hematopoietic transcription factor GATA binding protein-1 (GATA1) are found in megakaryoblasts from nearly all individuals with Down syndrome with transient myeloproliferative disorder (TMD, also called transient leukemia) and the related acute megakaryoblastic leukemia (DS-AMKL, also called DS-AML M7).
  • Our observations raise the possibility that the target cells in other leukemias of infancy and early childhood are distinct from those in adult leukemias and underscore the interplay between specific oncoproteins and potential target cells.
  • [MeSH-minor] Adult. Age Factors. Animals. Cell Differentiation. Cells, Cultured. Down Syndrome / genetics. Embryo, Mammalian. Erythroid-Specific DNA-Binding Factors. GATA1 Transcription Factor. Gene Targeting. Hematopoiesis / genetics. Humans. Infant. Leukemia, Megakaryoblastic, Acute / genetics. Liver / cytology. Liver / embryology. Megakaryocytes. Mice. Transfection


26. Klusmann JH, Godinho FJ, Heitmann K, Maroz A, Koch ML, Reinhardt D, Orkin SH, Li Z: Developmental stage-specific interplay of GATA1 and IGF signaling in fetal megakaryopoiesis and leukemogenesis. Genes Dev; 2010 Aug 1;24(15):1659-72
SciCrunch. ArrayExpress: Data: Microarray .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Oncogene-mediated transformation of hematopoietic cells has been studied extensively, but little is known about the molecular basis for restriction of oncogenes to certain target cells and differential cellular context-specific requirements for oncogenic transformation between infant and adult leukemias.
  • Here, we address the vexing issue of how developmental restriction is achieved in Down syndrome acute megakaryoblastic leukemia (DS-AMKL), characterized by the triad of fetal origin, mutated GATA1 (GATA1s), and trisomy 21.
  • Fetal but not adult megakaryocytic progenitors are dependent on this pathway.
  • Our study underscores context-dependent requirements during oncogenesis, and explains resistance to transformation of ostensibly similar adult progenitors.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Dev. 1989 Apr;3(4):527-36 [2721961.001]
  • [Cites] Nat Genet. 2005 Nov;37(11):1289-95 [16200064.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jan 2;98(1):31-6 [11134512.001]
  • [Cites] Cell. 2001 Oct 19;107(2):247-58 [11672531.001]
  • [Cites] Genes Dev. 2002 Jan 15;16(2):245-56 [11799067.001]
  • [Cites] Lancet Oncol. 2001 Jul;2(7):429-36 [11905737.001]
  • [Cites] Nat Genet. 2002 Sep;32(1):148-52 [12172547.001]
  • [Cites] Science. 2002 Oct 18;298(5593):601-4 [12228721.001]
  • [Cites] Blood. 2003 Jun 1;101(11):4333-41 [12576332.001]
  • [Cites] Mol Cell Biol. 2003 Jul;23(14):5031-42 [12832487.001]
  • [Cites] Blood. 2003 Oct 15;102(8):2960-8 [12816863.001]
  • [Cites] Oncogene. 2004 Jan 8;23(1):179-91 [14712223.001]
  • [Cites] Cell. 1991 Feb 22;64(4):849-59 [1997210.001]
  • [Cites] Blood. 1992 Aug 1;80(3):575-81 [1638017.001]
  • [Cites] Cell. 1993 Oct 8;75(1):73-82 [8402902.001]
  • [Cites] J Clin Invest. 1994 Jul;94(1):320-7 [8040273.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Oct 24;92(22):10302-6 [7479772.001]
  • [Cites] Mol Cell Biol. 1996 Feb;16(2):685-93 [8552097.001]
  • [Cites] J Biol Chem. 1996 May 3;271(18):10425-8 [8631833.001]
  • [Cites] Mol Cell Biol. 1997 Sep;17(9):5227-35 [9271400.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3932-9 [16109773.001]
  • [Cites] Blood. 2006 Feb 15;107(4):1570-81 [16249385.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 28;103(9):3339-44 [16492768.001]
  • [Cites] Nat Genet. 2006 Jul;38(7):807-12 [16783379.001]
  • [Cites] Nature. 2006 Aug 17;442(7104):818-22 [16862118.001]
  • [Cites] J Clin Invest. 2006 Oct;116(10):2808-16 [17016561.001]
  • [Cites] Nature. 2006 Nov 16;444(7117):364-8 [17093407.001]
  • [Cites] Cell. 2006 Dec 1;127(5):871-4 [17129771.001]
  • [Cites] Nat Cell Biol. 2007 Mar;9(3):339-46 [17277770.001]
  • [Cites] Cell. 2007 Aug 10;130(3):470-83 [17655922.001]
  • [Cites] Blood. 2007 Sep 15;110(6):2128-31 [17576817.001]
  • [Cites] Oncogene. 2007 Nov 1;26(50):7132-42 [17486056.001]
  • [Cites] Blood. 2008 Mar 15;111(6):2991-8 [18182574.001]
  • [Cites] Leukemia. 2008 Mar;22(3):521-9 [18094719.001]
  • [Cites] Oncogene. 2008 Jun 19;27(27):3831-44 [18246120.001]
  • [Cites] Blood. 2008 Dec 1;112(12):4507-11 [18689547.001]
  • [Cites] Blood. 2008 Dec 1;112(12):4503-6 [18812473.001]
  • [Cites] Nat Rev Cancer. 2008 Dec;8(12):915-28 [19029956.001]
  • [Cites] PLoS Biol. 2009 Jun 9;7(6):e1000123 [19513100.001]
  • [Cites] Genes Dev. 2010 Mar 1;24(5):478-90 [20194440.001]
  • [Cites] Blood. 2010 Apr 8;115(14):2928-37 [20154221.001]
  • [Cites] Proc Natl Acad Sci U S A. 2010 Apr 27;107(17):7799-804 [20385801.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):3130-5 [14976243.001]
  • [Cites] Blood. 2004 Apr 1;103(7):2513-21 [14592820.001]
  • [Cites] Genes Dev. 2004 Oct 1;18(19):2336-41 [15371326.001]
  • [Cites] Oncogene. 1998 Aug 13;17(6):769-80 [9715279.001]
  • [Cites] Mol Cell Biol. 1999 Jul;19(7):4672-83 [10373516.001]
  • [Cites] Blood. 2005 Mar 15;105(6):2527-34 [15550488.001]
  • [Cites] Nat Genet. 2005 Jun;37(6):613-9 [15895080.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50 [16199517.001]
  • [Cites] Nature. 1990 May 3;345(6270):78-80 [2330056.001]
  • (PMID = 20679399.001).
  • [ISSN] 1549-5477
  • [Journal-full-title] Genes & development
  • [ISO-abbreviation] Genes Dev.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL032259; United States / Howard Hughes Medical Institute / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / E2F Transcription Factors; 0 / GATA1 Transcription Factor; 0 / GATA1 protein, human; 0 / Gata1 protein, mouse; 0 / Intracellular Signaling Peptides and Proteins; 0 / Somatomedins; 0 / Transcription Factor DP1; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.1.1 / mTOR protein, mouse; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  • [Other-IDs] NLM/ PMC2912563
  •  go-up   go-down


27. Cloos J, Goemans BF, Hess CJ, van Oostveen JW, Waisfisz Q, Corthals S, de Lange D, Boeckx N, Hählen K, Reinhardt D, Creutzig U, Schuurhuis GJ, Zwaan ChM, Kaspers GJ: Stability and prognostic influence of FLT3 mutations in paired initial and relapsed AML samples. Leukemia; 2006 Jul;20(7):1217-20
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In acute myeloid leukemia (AML), activating mutations in the fms-like tyrosine kinase 3 (FLT3) gene predict poor prognosis.
  • We determined FLT3 internal tandem duplications (FLT3/ITD) and D835 point mutations in paired initial and relapse samples from 80 pediatric and adult AML patients.
  • [MeSH-major] Leukemia, Myeloid, Acute / epidemiology. Leukemia, Myeloid, Acute / genetics. Point Mutation. fms-Like Tyrosine Kinase 3 / genetics
  • [MeSH-minor] Adolescent. Adult. Female. Genetic Markers. Genetic Predisposition to Disease / epidemiology. Humans. Leukemia, Erythroblastic, Acute / genetics. Leukemia, Megakaryoblastic, Acute / genetics. Leukemia, Monocytic, Acute / genetics. Leukemia, Myelomonocytic, Acute / genetics. Leukemia, Promyelocytic, Acute / genetics. Male. Neoplasm, Residual / epidemiology. Neoplasm, Residual / genetics. Prognosis. Recurrence. Risk Factors. Tandem Repeat Sequences

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16642044.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Genetic Markers; EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
  •  go-up   go-down


28. Raffel GD, Mercher T, Shigematsu H, Williams IR, Cullen DE, Akashi K, Bernard OA, Gilliland DG: Ott1(Rbm15) has pleiotropic roles in hematopoietic development. Proc Natl Acad Sci U S A; 2007 Apr 3;104(14):6001-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OTT1(RBM15) was originally described as a 5' translocation partner of the MAL(MKL1) gene in t(1,22)(p13;q13) infant acute mega karyocytic leukemia.
  • To define the role of OTT1 in hematopoiesis and help elucidate the mechanism of t(1,22) acute megakaryocytic leukemia pathogenesis, a conditional allele of Ott1 was generated in mice.
  • Deletion of Ott1 in adult mice caused a loss of peripheral B cells due to a block in pro/pre-B differentiation.
  • There is myeloid and megakaryocytic expansion in spleen and bone marrow, an increase in the Lin(-)Sca-1(+)c-Kit(+) compartment that includes hematopoietic stem cells, and a shift in progenitor fate toward granulocyte differentiation.
  • These data show a requirement for Ott1 in B lymphopoiesis, and inhibitory roles in the myeloid, megakaryocytic, and progenitor compartments.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • SciCrunch. Marmoset Gene list: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Annu Rev Immunol. 2001;19:595-621 [11244048.001]
  • [Cites] Cell. 2000 Sep 15;102(6):753-63 [11030619.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 May 8;98(10):5776-9 [11344311.001]
  • [Cites] Nat Genet. 2001 Jul;28(3):220-1 [11431691.001]
  • [Cites] Mol Cell. 2002 Mar;9(3):611-23 [11931768.001]
  • [Cites] Dev Cell. 2002 Jul;3(1):137-47 [12110174.001]
  • [Cites] Nature. 2002 Sep 12;419(6903):182-5 [12226669.001]
  • [Cites] EMBO J. 2002 Oct 15;21(20):5417-26 [12374742.001]
  • [Cites] Immunity. 2003 Feb;18(2):301-12 [12594956.001]
  • [Cites] Cell. 2003 May 2;113(3):329-42 [12732141.001]
  • [Cites] Genes Dev. 2003 Aug 1;17(15):1909-20 [12897056.001]
  • [Cites] Nat Immunol. 2004 Mar;5(3):247-53 [14985712.001]
  • [Cites] Annu Rev Immunol. 2004;22:55-79 [15032574.001]
  • [Cites] Immunol Rev. 2004 Aug;200:115-31 [15242400.001]
  • [Cites] Immunol Rev. 2004 Aug;200:182-96 [15242405.001]
  • [Cites] BMC Bioinformatics. 2004 Jul 7;5:91 [15239844.001]
  • [Cites] J Mol Med (Berl). 2004 Sep;82(9):592-9 [15184986.001]
  • [Cites] Blood. 1991 Aug 1;78(3):748-52 [1859887.001]
  • [Cites] Cancer Genet Cytogenet. 1991 Jul 15;54(2):239-43 [1884357.001]
  • [Cites] Cell. 1994 Dec 2;79(5):893-900 [8001126.001]
  • [Cites] Science. 1995 Sep 8;269(5229):1427-9 [7660125.001]
  • [Cites] Cell. 1997 Nov 28;91(5):661-72 [9393859.001]
  • [Cites] Mol Cell Biol. 1998 Jul;18(7):4301-14 [9632814.001]
  • [Cites] Biochemistry. 1999 Aug 17;38(33):10678-90 [10451362.001]
  • [Cites] Immunity. 1999 Sep;11(3):299-308 [10514008.001]
  • [Cites] Immunity. 2004 Dec;21(6):853-63 [15589173.001]
  • [Cites] BMC Dev Biol. 2004;4:15 [15596016.001]
  • [Cites] Blood. 2005 Jun 1;105(11):4272-81 [15701714.001]
  • [Cites] J Biol Chem. 2005 Nov 4;280(44):36935-45 [16129689.001]
  • [Cites] Curr Opin Hematol. 2006 Jan;13(1):7-14 [16319681.001]
  • [Cites] Semin Immunol. 2006 Feb;18(1):31-9 [16386923.001]
  • [Cites] Development. 1999 Dec;126(23):5373-85 [10556062.001]
  • [Cites] Genetics. 2000 Feb;154(2):695-712 [10655223.001]
  • [Cites] Development. 2000 Apr;127(7):1517-29 [10704397.001]
  • [Cites] Nature. 2000 Mar 9;404(6774):193-7 [10724173.001]
  • [Cites] EMBO J. 2000 Apr 17;19(8):1827-38 [10775267.001]
  • [Cites] Nature. 2000 Sep 21;407(6802):383-6 [11014194.001]
  • [Cites] Genetics. 2000 Oct;156(2):733-48 [11014820.001]
  • [Cites] Genes Dev. 2001 May 1;15(9):1140-51 [11331609.001]
  • (PMID = 17376872.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K08 CA111399; United States / NCI NIH HHS / CA / P01 CA066996; United States / NCI NIH HHS / CA / R01 CA66996
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Drosophila Proteins; 0 / RNA-Binding Proteins; 0 / Rbm15 protein, mouse
  • [Other-IDs] NLM/ PMC1851606
  •  go-up   go-down


29. Bhargava P, Kallakury BV, Ross JS, Azumi N, Bagg A: CD79a is heterogeneously expressed in neoplastic and normal myeloid precursors and megakaryocytes in an antibody clone-dependent manner. Am J Clin Pathol; 2007 Aug;128(2):306-13
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The reported frequency of CD79a expression in acute myeloid leukemias (AML) ranges from 0% to 90%.
  • Of 7 acute promyelocytic leukemia (APL) cases, 6 (86%) stained for CD79a with clones HM47/A9 (Novocastra, Newcastle Upon Tyne, England) and HM57 (DAKO, Carpinteria, CA) but were negative with clones 11E3 (Novocastra), and JCB117 (DAKO).
  • Half of 6 acute megakaryoblastic leukemia (AMKL) cases and normal megakaryocytes in 14 (67%) of 21 cases were immunoreactive using clone 11D10 (Novocastra).
  • [MeSH-major] Antigens, CD79 / analysis. Bone Marrow Cells / chemistry. Leukemia, Myeloid, Acute / metabolism. Megakaryocytes / chemistry
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / immunology. Female. Humans. Immunohistochemistry. Infant. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17638667.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD79; 0 / CD79A protein, human
  •  go-up   go-down


30. Lebwaze BM, Le Tourneau A, Rio B, Perrot JY, Heuberger L, Kabongo JM, Kalengayi RM, Molina T, Diebold J, Audouin J: [Histopathologic pattern of hyperplasia of bone marrow hematogones (medullar b lymphoid cell precursors) occurring after treatment of idiopathic myelofibrosis]. Ann Pathol; 2008 Feb;28(1):27-31
Genetic Alliance. consumer health - Myelofibrosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histopathology and immunohistochemistry identified these cells as hyperplasia of hematogones and not a transformation into lymphoblastic acute leukaemia.
  • [MeSH-major] B-Lymphocytes / pathology. Bone Marrow / pathology. Hyperplasia / pathology. Leukemia, Megakaryoblastic, Acute / pathology. Lymphocytes / pathology. Primary Myelofibrosis / pathology
  • [MeSH-minor] Adult. Fatal Outcome. Humans. Male. Pancytopenia / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18538711.001).
  • [ISSN] 0242-6498
  • [Journal-full-title] Annales de pathologie
  • [ISO-abbreviation] Ann Pathol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


31. Gilles L, Bluteau D, Boukour S, Chang Y, Zhang Y, Robert T, Dessen P, Debili N, Bernard OA, Vainchenker W, Raslova H: MAL/SRF complex is involved in platelet formation and megakaryocyte migration by regulating MYL9 (MLC2) and MMP9. Blood; 2009 Nov 5;114(19):4221-32
SciCrunch. ArrayExpress: Data: Microarray .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Megakaryoblastic leukemia 1 (MAL) is a transcriptional coactivator of serum response factor (SRF).
  • In acute megakaryoblastic leukemia, the MAL gene is translocated and fused with the gene encoding one twenty-two (OTT).
  • Herein, we show that MAL expression increases during the late differentiation steps of neonate and adult human megakaryopoiesis and localized into the nucleus after Rho GTPase activation by adhesion on collagen I or convulxin.
  • [MeSH-minor] Adult. Cell Differentiation. Cell Line. Cell Movement / genetics. Cell Movement / physiology. Fetal Blood / cytology. Focal Adhesions. Gene Expression Profiling. Humans. In Vitro Techniques. Infant, Newborn. Multiprotein Complexes. Oligonucleotide Array Sequence Analysis. RNA, Small Interfering / genetics. Thrombopoiesis. Trans-Activators. rho GTP-Binding Proteins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Blood. 2009 Nov 5;114(19):3977-8 [19892723.001]
  • (PMID = 19724058.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / MKL1 protein, human; 0 / Multiprotein Complexes; 0 / Myosin Light Chains; 0 / Oncogene Proteins, Fusion; 0 / RNA, Small Interfering; 0 / SRF protein, human; 0 / Serum Response Factor; 0 / Trans-Activators; 0 / myosin light chain 2; EC 3.4.24.35 / Matrix Metalloproteinase 9; EC 3.6.1.- / Cardiac Myosins; EC 3.6.5.2 / rho GTP-Binding Proteins
  •  go-up   go-down


32. Hollanda LM, Lima CS, Cunha AF, Albuquerque DM, Vassallo J, Ozelo MC, Joazeiro PP, Saad ST, Costa FF: An inherited mutation leading to production of only the short isoform of GATA-1 is associated with impaired erythropoiesis. Nat Genet; 2006 Jul;38(7):807-12
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Acquired somatic mutations in exon 2 of the hematopoietic transcription factor GATA-1 have been found in individuals with Down syndrome with both transient myeloproliferative disorder and acute megakaryoblastic leukemia.
  • Experiments in mice suggest that GATA-1s supports normal adult megakaryopoiesis, platelet formation and erythropoiesis.
  • Moreover, this is the first study to indicate that a germline splicing mutation does not lead to leukemia in the absence of other cooperating events, such as Down syndrome.
  • [MeSH-minor] Adolescent. Adult. Anemia, Macrocytic / blood. Anemia, Macrocytic / genetics. Anemia, Macrocytic / pathology. Animals. Blood Platelets / metabolism. Blood Platelets / ultrastructure. Bone Marrow / pathology. Child. Child, Preschool. Female. Humans. Infant. Male. Mice. Microscopy, Electron. Pedigree. Protein Isoforms / chemistry. Protein Isoforms / genetics. Protein Isoforms / metabolism

  • COS Scholar Universe. author profiles.
  • SciCrunch. OMIM: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Nat Genet. 2006 Jul;38(7):741-2 [16804537.001]
  • (PMID = 16783379.001).
  • [ISSN] 1061-4036
  • [Journal-full-title] Nature genetics
  • [ISO-abbreviation] Nat. Genet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / GATA1 Transcription Factor; 0 / GATA1 protein, human; 0 / Protein Isoforms
  •  go-up   go-down


33. Majewski IJ, Metcalf D, Mielke LA, Krebs DL, Ellis S, Carpinelli MR, Mifsud S, Di Rago L, Corbin J, Nicola NA, Hilton DJ, Alexander WS: A mutation in the translation initiation codon of Gata-1 disrupts megakaryocyte maturation and causes thrombocytopenia. Proc Natl Acad Sci U S A; 2006 Sep 19;103(38):14146-51
SciCrunch. Marmoset Gene list: Data: Gene Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have generated mice from a N-ethyl-N-nitrosourea mutagenesis screen that carry a mutation in the translation initiation codon of Gata-1, termed Plt13, which is equivalent to mutations found in patients with acute megakaryoblastic leukemia and Down syndrome.
  • Adult Gata-1Plt13/+ females were not anemic, but they were thrombocytopenic and accumulated abnormal megakaryocytes without a concomitant increase in megakaryocyte progenitor cells.
  • Gata-1Plt13/+ mice contained large numbers of blast-like colony-forming cells, particularly in the fetal liver, but also in adult spleen and bone marrow, from which continuous mast cells lines were readily derived.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. N-NITROSO-N-ETHYLUREA .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] EMBO J. 2001 Sep 17;20(18):5250-60 [11566888.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2803-8 [10706630.001]
  • [Cites] J Exp Med. 2002 Jun 3;195(11):1387-95 [12045237.001]
  • [Cites] Blood. 2002 Sep 15;100(6):2040-5 [12200364.001]
  • [Cites] Nat Genet. 2002 Sep;32(1):148-52 [12172547.001]
  • [Cites] J Exp Med. 2003 Feb 3;197(3):281-96 [12566412.001]
  • [Cites] Blood. 2003 Aug 1;102(3):981-6 [12649131.001]
  • [Cites] Blood. 2003 Oct 15;102(8):2960-8 [12816863.001]
  • [Cites] Leukemia. 2003 Nov;17(11):2250-2 [12931214.001]
  • [Cites] Thromb Haemost. 2004 Jan;91(1):129-40 [14691578.001]
  • [Cites] Genes Dev. 1990 Nov;4(11):1886-98 [2276623.001]
  • [Cites] Genes Dev. 1994 May 15;8(10):1184-97 [7926723.001]
  • [Cites] Mol Cell Biol. 1995 Feb;15(2):634-41 [7823932.001]
  • [Cites] Cell. 1995 Jun 2;81(5):695-704 [7774011.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11598-602 [8524811.001]
  • [Cites] Blood. 1996 Mar 15;87(6):2162-70 [8630375.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Oct 29;93(22):12355-8 [8901585.001]
  • [Cites] EMBO J. 1997 Jul 1;16(13):3965-73 [9233806.001]
  • [Cites] Blood. 1998 Jan 15;91(2):450-7 [9427697.001]
  • [Cites] Blood. 1999 May 1;93(9):2867-75 [10216081.001]
  • [Cites] Nat Rev Cancer. 2005 Jan;5(1):11-20 [15630411.001]
  • [Cites] Nat Genet. 2005 Jun;37(6):613-9 [15895080.001]
  • [Cites] Blood. 2005 Aug 15;106(4):1223-31 [15860665.001]
  • [Cites] Blood. 2006 Jan 1;107(1):87-97 [16144799.001]
  • [Cites] Nat Genet. 2006 Jul;38(7):807-12 [16783379.001]
  • [Cites] Nat Genet. 2000 Mar;24(3):266-70 [10700180.001]
  • [Cites] Blood. 2001 Nov 1;98(9):2681-8 [11675338.001]
  • (PMID = 16966598.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Alkylating Agents; 0 / Codon; 0 / GATA1 Transcription Factor; 0 / Gata1 protein, mouse; 0 / Protein Isoforms; P8M1T4190R / Ethylnitrosourea
  • [Other-IDs] NLM/ PMC1599926
  •  go-up   go-down


34. Spinelli SL, Casey AE, Pollock SJ, Gertz JM, McMillan DH, Narasipura SD, Mody NA, King MR, Maggirwar SB, Francis CW, Taubman MB, Blumberg N, Phipps RP: Platelets and megakaryocytes contain functional nuclear factor-kappaB. Arterioscler Thromb Vasc Biol; 2010 Mar;30(3):591-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Platelets and megakaryocytes contain functional nuclear factor-kappaB.
  • OBJECTIVE: To investigate the presence and role of NF-kappaB proteins in megakaryocytes and platelets.
  • The nuclear factor-kappaB (NF-kappaB) transcription factor family is well known for its role in eliciting inflammation and promoting cell survival.
  • We discovered that human megakaryocytes and platelets express the majority of NF-kappaB family members, including the regulatory inhibitor-kappaB (I-kappaB) and I-kappa kinase (IKK) molecules.
  • METHODS AND RESULTS: Anucleate platelets exposed to NF-kappaB inhibitors demonstrated impaired fundamental functions involved in repairing vascular injury and thrombus formation.
  • Specifically, NF-kappaB inhibition diminished lamellapodia formation, decreased clot retraction times, and reduced thrombus stability.
  • Moreover, inhibition of I-kappaB-alpha phosphorylation (BAY-11-7082) reverted fully spread platelets back to a spheroid morphology.
  • Addition of recombinant IKK-beta or I-kappaB-alpha protein to BAY inhibitor-treated platelets partially restored platelet spreading in I-kappaB-alpha inhibited platelets, and addition of active IKK-beta increased endogenous I-kappaB-alpha phosphorylation levels.
  • CONCLUSIONS: These novel findings support a crucial and nonclassical role for the NF-kappaB family in modulating platelet function and reveal that platelets are sensitive to NF-kappaB inhibitors.
  • As NF-kappaB inhibitors are being developed as antiinflammatory and anticancer agents, they may have unintended effects on platelets.
  • On the basis of these data, NF-kappaB is also identified as a new target to dampen unwanted platelet activation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Chem. 2004 Dec;50(12):2271-8 [15472037.001]
  • [Cites] Cell. 2005 Aug 12;122(3):379-91 [16096058.001]
  • [Cites] J Biol Chem. 2005 Nov 25;280(47):39474-84 [16195235.001]
  • [Cites] Oncogene. 2006 Oct 30;25(51):6680-4 [17072321.001]
  • [Cites] Circ Res. 2007 Jan 5;100(1):27-40 [17204662.001]
  • [Cites] Blood. 2007 Mar 1;109(5):1975-83 [17110454.001]
  • [Cites] J Biol Chem. 2007 Apr 6;282(14):10146-52 [17276989.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3284-90 [17170121.001]
  • [Cites] Blood. 2007 May 1;109(9):3679-86 [17213284.001]
  • [Cites] Blood. 2007 May 1;109(9):3741-4 [17213293.001]
  • [Cites] Cancer Res. 2007 May 15;67(10):4767-73 [17510405.001]
  • [Cites] Thromb Haemost. 2008 Jan;99(1):86-95 [18217139.001]
  • [Cites] Blood. 2008 Jul 1;112(1):90-9 [18310501.001]
  • [Cites] Blood. 2008 Nov 15;112(10):4051-60 [18755987.001]
  • [Cites] J Cell Biol. 2001 Aug 6;154(3):485-90 [11489912.001]
  • [Cites] J Biol Chem. 2001 Jun 15;276(24):21317-24 [11287411.001]
  • [Cites] J Thromb Haemost. 2009 Aug;7(8):1333-43 [19566544.001]
  • [Cites] J Cell Biol. 2002 Apr 15;157(2):265-75 [11940607.001]
  • [Cites] Thromb Res. 2002 May 15;106(4-5):199-203 [12297126.001]
  • [Cites] J Biol Chem. 2003 Jan 31;278(5):2963-8 [12433922.001]
  • [Cites] Blood. 2003 Mar 15;101(6):2285-93 [12433680.001]
  • [Cites] J Biol Chem. 2003 Aug 29;278(35):32861-71 [12813046.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2003 Sep 1;23(9):1690-6 [12855480.001]
  • [Cites] Thromb Haemost. 2003 Oct;90(4):738-48 [14515197.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2003 Dec;23(12):2131-7 [14500287.001]
  • [Cites] Nat Immunol. 2004 Jan;5(1):104-12 [14691478.001]
  • [Cites] J Immunol. 2004 May 1;172(9):5297-303 [15100268.001]
  • [Cites] Blood. 2004 Sep 1;104(5):1361-8 [15130939.001]
  • [Cites] Eur J Biochem. 1987 Apr 1;164(1):189-95 [3830180.001]
  • [Cites] Crit Rev Oncog. 1992;3(4):401-46 [1384720.001]
  • [Cites] Genes Dev. 1992 Dec;6(12A):2352-63 [1459457.001]
  • [Cites] Genes Dev. 1997 Feb 15;11(4):463-75 [9042860.001]
  • [Cites] J Biol Chem. 1997 Aug 22;272(34):21096-103 [9261113.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 May 12;95(10):5556-61 [9576921.001]
  • [Cites] J Biol Chem. 1998 May 22;273(21):12779-85 [9582304.001]
  • (PMID = 20042710.001).
  • [ISSN] 1524-4636
  • [Journal-full-title] Arteriosclerosis, thrombosis, and vascular biology
  • [ISO-abbreviation] Arterioscler. Thromb. Vasc. Biol.
  • [Language] ENG
  • [Grant] United States / NIDCR NIH HHS / DE / T32-DE07165; United States / NHLBI NIH HHS / HL / R21 HL086367; United States / NHLBI NIH HHS / HL / HL086367; United States / NINDS NIH HHS / NS / R01 NS054578; United States / NHLBI NIH HHS / HL / RC1 HL100051; United States / NIDCR NIH HHS / DE / DE011390; United States / NHLBI NIH HHS / HL / R01 HL078603-04; United States / NIEHS NIH HHS / ES / ES01247; United States / NHLBI NIH HHS / HL / HL095467-01A1; United States / NIEHS NIH HHS / ES / P30 ES001247; United States / NIEHS NIH HHS / ES / P30 ES001247-269015; United States / NHLBI NIH HHS / HL / R01 HL095467; United States / NHLBI NIH HHS / HL / HL095467; United States / NIDCR NIH HHS / DE / R01 DE011390; United States / NHLBI NIH HHS / HL / RC1 HL100051-01; United States / NINDS NIH HHS / NS / NS054578; United States / NHLBI NIH HHS / HL / RC1HL100051; United States / NHLBI NIH HHS / HL / HL078603-04; United States / NHLBI NIH HHS / HL / R01 HL078603; United States / NIDCR NIH HHS / DE / T32 DE007165; United States / NHLBI NIH HHS / HL / R01 HL095467-01A1; United States / NHLBI NIH HHS / HL / HL078603; United States / CCR NIH HHS / RC / HL100051-01; United States / NIEHS NIH HHS / ES / ES001247-269015; United States / NIDCR NIH HHS / DE / R01 DE011390-22; United States / NIDCR NIH HHS / DE / DE011390-22
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 3-(4-methylphenylsulfonyl)-2-propenenitrile; 0 / NF-kappa B; 0 / NF-kappa B p50 Subunit; 0 / Nitriles; 0 / Sulfones; 0 / Transcription Factor RelA
  • [Other-IDs] NLM/ NIHMS172813; NLM/ PMC2853005
  •  go-up   go-down


35. Larussa D, Grisetti S, Pilozzi E, Concorsi P, Pisa R, Ruco L, Antinori A: Acute megakaryoblastic leukemia in a patient receiving HAART. Am J Hematol; 2005 Sep;80(1):89-90
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute megakaryoblastic leukemia in a patient receiving HAART.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / drug therapy. Antiretroviral Therapy, Highly Active / adverse effects. Leukemia, Megakaryoblastic, Acute / chemically induced
  • [MeSH-minor] Adult. Biopsy. Blast Crisis. Bone Marrow / pathology. Humans. Male


36. Brahmanday GR, Gheorghe G, Jaiyesimi IA, Orazi A, Zekman R, Parikh R, Wills SM, Einhorn LH: Primary mediastinal germ cell tumor evolving into an extramedullary acute megakaryoblastic leukemia causing cord compression. J Clin Oncol; 2008 Oct 1;26(28):4686-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary mediastinal germ cell tumor evolving into an extramedullary acute megakaryoblastic leukemia causing cord compression.
  • [MeSH-major] Leukemia, Megakaryoblastic, Acute / pathology. Mediastinal Neoplasms / pathology. Neoplasms, Germ Cell and Embryonal / pathology. Spinal Cord Compression / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Biopsy. Combined Modality Therapy. Diagnosis, Differential. Humans. Male. Tomography, Emission-Computed. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Acute Megakaryoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18824716.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


37. Corm S, Renneville A, Rad-Quesnel E, Grardel N, Preudhomme C, Quesnel B: Successful treatment of imatinib-resistant acute megakaryoblastic leukemia with e6a2 BCR/ABL: use of dasatinib and reduced-conditioning stem-cell transplantation. Leukemia; 2007 Nov;21(11):2376-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of imatinib-resistant acute megakaryoblastic leukemia with e6a2 BCR/ABL: use of dasatinib and reduced-conditioning stem-cell transplantation.
  • [MeSH-major] Drug Resistance, Neoplasm. Fusion Proteins, bcr-abl / genetics. Fusion Proteins, bcr-abl / physiology. Leukemia, Megakaryoblastic, Acute / drug therapy. Leukemia, Megakaryoblastic, Acute / genetics. Piperazines / pharmacology. Pyrimidines / pharmacology
  • [MeSH-minor] Adult. Aged. Benzamides. Dasatinib. Female. Hematopoietic Stem Cell Transplantation / methods. Humans. Imatinib Mesylate. Male. Middle Aged. Recombinant Fusion Proteins / chemistry. Thiazoles / therapeutic use. Transplantation Conditioning. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Megakaryoblastic Leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17554376.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 0 / Recombinant Fusion Proteins; 0 / Thiazoles; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.2 / Fusion Proteins, bcr-abl; RBZ1571X5H / Dasatinib
  •  go-up   go-down


38. Kiyoi H, Yamaji S, Kojima S, Naoe T: JAK3 mutations occur in acute megakaryoblastic leukemia both in Down syndrome children and non-Down syndrome adults. Leukemia; 2007 Mar;21(3):574-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] JAK3 mutations occur in acute megakaryoblastic leukemia both in Down syndrome children and non-Down syndrome adults.
  • [MeSH-major] Down Syndrome / complications. Janus Kinase 3 / genetics. Leukemia, Megakaryoblastic, Acute / genetics. Myeloproliferative Disorders / genetics. Neoplasm Proteins / genetics
  • [MeSH-minor] Adult. Binding Sites / genetics. Child. DNA Mutational Analysis. DNA, Neoplasm / genetics. Disease Progression. Enzyme Activation / genetics. Female. GATA1 Transcription Factor / genetics. Genes, ras. Genetic Predisposition to Disease. Humans. Interleukin Receptor Common gamma Subunit / metabolism. Male. Protein Structure, Tertiary. Structure-Activity Relationship. Tumor Suppressor Protein p53 / genetics. fms-Like Tyrosine Kinase 3 / genetics

  • Genetic Alliance. consumer health - Acute Megakaryoblastic Leukemia.
  • Genetic Alliance. consumer health - Down Syndrome.
  • MedlinePlus Health Information. consumer health - Down Syndrome.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17252020.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Comparative Study; Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / GATA1 Transcription Factor; 0 / GATA1 protein, human; 0 / Interleukin Receptor Common gamma Subunit; 0 / JAK3 protein, human; 0 / Neoplasm Proteins; 0 / Tumor Suppressor Protein p53; EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3; EC 2.7.10.2 / Janus Kinase 3
  •  go-up   go-down


39. Kawaguchi H, Hitzler JK, Ma Z, Morris SW: RBM15 and MKL1 mutational screening in megakaryoblastic leukemia cell lines and clinical samples. Leukemia; 2005 Aug;19(8):1492-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] RBM15 and MKL1 mutational screening in megakaryoblastic leukemia cell lines and clinical samples.
  • [MeSH-major] DNA-Binding Proteins / genetics. Leukemia, Megakaryoblastic, Acute / genetics. Oncogene Proteins, Fusion / genetics. Polymorphism, Single Nucleotide. RNA-Binding Proteins / genetics
  • [MeSH-minor] Adult. Aged. DNA Mutational Analysis. Genotype. Humans. Infant. Middle Aged. Trans-Activators. Tumor Cells, Cultured

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15920491.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-27165; United States / NCI NIH HHS / CA / CA-87064
  • [Publication-type] Letter; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / MKL1 protein, human; 0 / Oncogene Proteins, Fusion; 0 / RBM15 protein, human; 0 / RNA-Binding Proteins; 0 / Trans-Activators
  •  go-up   go-down


40. Ikdahl T, Josefsen D, Jakobsen E, Delabie J, Fosså SD: Concurrent mediastinal germ-cell tumour and haematological malignancy: case report and short review of literature. Acta Oncol; 2008;47(3):466-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Histiocytic Sarcoma / pathology. Leukemia, Megakaryoblastic, Acute / pathology. Mediastinal Neoplasms / pathology. Neoplasms, Germ Cell and Embryonal / pathology. Neoplasms, Multiple Primary
  • [MeSH-minor] Adult. Carcinoma, Embryonal / complications. Carcinoma, Embryonal / pathology. Chest Pain / etiology. Cough / etiology. Endodermal Sinus Tumor / complications. Endodermal Sinus Tumor / pathology. Fatal Outcome. Fatigue / etiology. Fever / etiology. Gastrointestinal Hemorrhage / etiology. Humans. Leukemic Infiltration. Male. Teratocarcinoma / pathology. Teratoma / complications. Teratoma / pathology. Testis / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18348004.001).
  • [ISSN] 1651-226X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Letter; Review
  • [Publication-country] Norway
  • [Number-of-references] 12
  •  go-up   go-down






Advertisement